Navigation Links
Alexza Prices $16.1 Million Registered Direct Offering
Date:5/3/2011

the offering and the accompanying base prospectus may also be accessed on the SEC website, http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Alexza nor shall there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.  (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and submitted a New Drug Application, or NDA, for AZ-004 in December 2009.  In October 2010, the Company received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration, or FDA, regarding its NDA for AZ-004.  A CRL is issued by the FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and that the application is not ready for ap
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
2. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
3. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
4. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
5. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
6. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
7. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
8. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
9. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
10. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
11. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... Partnership to Fight Chronic Disease (PFCD) released a public opinion poll ... new study analyzing the impact of increased cost sharing on patient ... to educate policy makers and the public on the costs of ... how the Iowa healthcare exchange could be ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Data from experimental work on the use,of ... this week at the,International Society for Heart and ... donors after cardiac death,(DCD), also known as non-heart-beating ... shortage of suitable donor organs for lung, and,possibly ...
... Institute,s NABTT ... Consortium -, ... expansion of the clinical program for the company,s lead,product candidate, BSI-201, ... first poly ADP-ribose polymerase,(PARP) inhibitor in BiPar,s DNA repair portfolio, crosses ...
Cached Medicine Technology:Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation 2Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation 3BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Deer Path of ... host a Valentine’s Day Happy Hour from 3 p.m. to 4 ... 12500 Regency Parkway in Huntley, Illinois, serves adults with physical disabilities ... event will include Valentine's Day treats, games and sweetheart-themed karaoke. , ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... This release is available in French . ... the Government of Canada,s commitment to strengthening Canada,s healthcare ... today funding for 25 policy-relevant research projects across six ... improving healthcare and health systems for Canadians," said Minister ...
... Develop Promising New Cancer Fighting Drug, Vemurafenib ... for Melanoma and Other Life-Threatening Diseases WASHINGTON, ... U.S. Department of Energy,s (DOE,s) national laboratories is ... to the swine flu, and, most recently, enabled ...
... Aug. 18 (HealthDay News) -- Black researchers are 10 ... receive research grants from the U.S. National Institutes of ... findings are unacceptable, NIH officials pledged immediate action to ... individual applicants between 2000 and 2006 reported that Asian ...
... , THURSDAY, Aug. 18 (HealthDay News) -- Many doctors continue ... guidelines say some women can wait much longer between tests. ... Katherine Roland, a behavioral scientist at the U.S. Centers for ... with the guidelines," Roland said. The downsides of too-frequent ...
... Several prominent cancer researchers are now joining forces in an ... tumors will be difficult to treat and to find out ... of use. The study is to be directed by Tobias ... The study involves a hundred cancer patients, suffering ...
... For the first time, researchers at Seattle ... using serial positron emission tomography (PET) scans, using ... effectiveness of estrogen-blocking and estrogen-depleting therapy in patients ... research are published online in Clinical Cancer ...
Cached Medicine News:Health News:Research improving health care 2Health News:DOE laboratories help develop promising new cancer fighting drug, vemurafenib 2Health News:Black Scientists Less Likely to Receive NIH Research Grants 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 3Health News:Major advanced cancer study to be led by Uppsala University 2Health News:PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients 2
To elevate, dissect, scrape and apply traction to bone and soft tissue....
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
Medicine Products: